Login / Signup

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.

Ewan M TomenyThomas HamptonPhuong Bich TranLaura RosuMphatso D PhiriKathryn A HaighJasper NidoiTom WingfieldEve Worrall
Published in: PharmacoEconomics (2024)
There is a need for increased rigour in the application, sensitivity testing and reporting of TB disability weights. Furthermore, there appears a desire among researchers to reflect elements of the tuberculosis experience beyond those allowed for by GBD disability weights.
Keyphrases
  • mycobacterium tuberculosis
  • multiple sclerosis
  • pulmonary tuberculosis
  • adverse drug
  • hiv aids
  • emergency department
  • antiretroviral therapy